CLDI

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Calidi is a clinical-stage immuno-oncology company developing allogeneic stem cell-based platforms to deliver oncolytic viruses for cancer treatment. Key programs include CLD-101 (NeuroNova) for high-grade glioma and CLD-201 (SuperNova) for solid tumors. The company has no approved products and generates no product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately 30% to $5.1 million from $7.2 million in Q1 2024. This improvement was driven by a 25% reduction in total operating expenses.
• Expense Reductions:
  • R&D Expenses: Decreased $0.3 million to $2.4 million, primarily due to lower salaries and reduced drug manufacturing/preclinical costs.
  • G&A Expenses: Decreased $1.4 million to $2.6 million, driven by lower stock-based compensation, reduced headcount, and decreased legal/settlement costs.
• Debt Repayment: Significant reduction in debt obligations. The company settled $1.5 million in term notes and bridge loans during the quarter. Total debt carrying value dropped from $3.8 million to $1.8 million.
• Capital Raising: The company raised approximately $10.1 million in gross proceeds through equity financings, including a January Confidentially Marketed Public Offering (CMPO), an At-The-Market (ATM) offering, and a March Registered Direct Offering.
• Warrant Liability: The fair value of warrant liabilities decreased from $128,000 to $87,000, contributing to a gain in "Other income (expenses), net."

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Cash on hand ($10.6 million) is insufficient to fund operations for the next year without additional financing.
• Outlook: The company expects to continue incurring significant operating losses. Future funding is required to advance clinical trials (CLD-101, CLD-201) and commercialization efforts. The company plans to raise capital through public/private equity or debt financings.
• Recent Executive Changes: Allan Camaisa resigned as CEO and Chairman effective April 21, 2025. Eric Poma, Ph.D., was appointed CEO and a Class I Director. James Schoeneck was appointed Chairman.
• Legal Proceedings:
  • Former CFO Litigation: Ongoing dispute with former Chief Accounting Officer Tony Kalajian regarding defamation and constructive discharge. A stay on the case was lifted in March 2025.
  • Securities Matter: A complaint filed by Mr. Yian Zeng regarding securities fraud remains pending with no settlement reached as of April 2025.
• Unusual Items: The company recognized $50,000 in grant income from the California Institute for Regenerative Medicine (CIRM). The Standby Equity Purchase Agreement (SEPA) with Yorkville was terminated in January 2025.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline and terms of any new financing agreements required to address the "substantial doubt" going concern warning.
• Dilution Risk: Review the terms of the March Registered Direct Offering and the significant increase in outstanding warrants (over 20 million shares) which may dilute existing shareholders.
• Debt Covenants: Confirm the repayment schedule for the remaining $1.75 million in debt, specifically the related party term notes and promissory notes.
• Clinical Milestones: Monitor the status of the CLD-101 Phase 1b/2 trial at Northwestern University, which is dependent on National Cancer Institute funding that was frozen in March 2025.
• Executive Transition: Assess the impact of the CEO transition on strategic direction and operational stability.